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Abstract
Background: Radiation-induced tinnitus is a side effect of radiotherapy in the inner ear for cancers of the head and
neck. Effective dose constraints for protecting the cochlea are under-reported. The aim of this study is to determine
the cochlea dose limitation to avoid causing tinnitus after head-and-neck cancer (HNC) intensity-modulated radiation
therapy (IMRT).
Methods: In total 211 patients with HNC were included; the side effects of radiotherapy were investigated for 422
inner ears in the cohort. Forty-nine of the four hundred and twenty-two samples (11.6 %) developed grade 2+ tinnitus
symptoms after IMRT, as diagnosed by a clinician. The Late Effects of Normal Tissues–Subjective, Objective,
Management, Analytic (LENT-SOMA) criteria were used for tinnitus evaluation. The logistic and Lyman-Kutcher-Burman
(LKB) normal tissue complication probability (NTCP) models were used for the analyses.
Results: The NTCP-fitted parameters were TD50 = 46.31 Gy (95 % CI, 41.46–52.50), γ50 = 1.27 (95 % CI, 1.02–1.55), and
TD50 = 46.52 Gy (95 % CI, 41.91–53.43), m = 0.35 (95 % CI, 0.30–0.42) for the logistic and LKB models, respectively. The
suggested guideline TD20 for the tolerance dose to produce a 20 % complication rate within a specific period of time
was TD20 = 33.62 Gy (95 % CI, 30.15–38.27) (logistic) and TD20 = 32.82 Gy (95 % CI, 29.58–37.69) (LKB).
Conclusions: To maintain the incidence of grade 2+ tinnitus toxicity <20 % in IMRT, we suggest that the mean dose
to the cochlea should be <32 Gy. However, models should not be extrapolated to other patient populations without
further verification and should first be confirmed before clinical implementation.
Background
Head-and-neck cancers (HNC) are some of the most
serious malignancies worldwide. Radiation therapy (RT)
is the mainstay of treatment, offered to almost 75 % of
all HNC patients with either curative or palliative intent.
Toxicities associated with RT represent important clin-
ical outcomes that can substantially reduce the patient’s
quality of life (QOL) and the ability of cancer patients to
tolerate and complete the planned course of treatment
[1]. During RT for HNC, the entire hearing apparatus
and/or parts of the auditory system receive high doses of
radiation during treatment, which can result in various
radiation-induced damages to the external, middle, and
inner ear [2, 3]. Morbidities associated with the inner
ear include a wide range of symptoms such as tinnitus,
labyrinthitis, canal paresis, vertigo/balance problems,
and sensori-neural hearing loss (SNHL) [2]. Hearing loss
and neurological defects have been investigated exten-
sively. However, radiation-induced tinnitus is under-
evaluated and under-reported.
The relationship between the dose of irradiation
received by the cochlea and the degree of tinnitus
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toxicity experienced is well recognized, but poorly quan-
tified [2, 4–6]. To our knowledge, no studies have
described the normal tissue complication probability
(NTCP) of the cochlea using tinnitus as the endpoint after
radiation therapy. In addition, there is no Quantitative
Analyses of Normal Tissue Effects in the Clinic
(QUANTEC) guideline for the cochlea relating to the
avoidance of tinnitus during intensity-modulated radi-
ation therapy (IMRT). The NTCP parameters should,
therefore, be determined to reveal the relationship
between dose–response and radiation-induced tinnitus
toxicity. Knowledge of the association between the dose
distribution in the organs at risk and the probability of
radiation-induced toxicity is becoming increasingly
important during IMRT-planning procedures [4].
In this study, we used two common NTCP models,
the logistic and the Lyman-Kutcher-Burman (LKB)
models, to quantify the relationship between the inci-
dence of tinnitus toxicity and the dose–response effects
in the cochlea with the aim of identifying a specific dose
relationship. The aim was to determine the best-fit
parameters of these well-known and established NTCP
models, and then identify the model that best describes
the dose–response relationship between the cochlea and
tinnitus after radiation therapy. The obtained results are
likely to reveal a dose–response constraint for the coch-
lea that can reduce the incidence of tinnitus in radiation
therapy using proper treatment planning.
Methods
Study population
In total 211 patients with HNC were included in this
study; the side effects of radiotherapy were investigated
for 422 inner ears in the cohort. All participants were
treated using IMRT between June 2007 and December
2010. The characteristics of the samples are listed in
Table 1. Any patients with problems related to the
vestibulo-cochlear nerve were excluded from analysis
because their hearing problems could be associated with
pathologies of the auditory system [5, 7]. The Institutional
Review Board of E-Da Hospital (EMRP-103-020) ap-
proved the study protocol, and all investigations were
performed in accordance with the relevant guidelines and
regulations.
A basic assumption, and a potential limitation, of the
present study was that the two ears of each patient could
be analyzed as independent variables. Patient age and
observation time were, therefore, the same for both ears,
and the dose and pre-therapeutic tinnitus levels could be
expected to show some correlation [8]. Based on the
suggestion by Honoré et al. [8], the maximum-likelihood
estimate of variance components was used to assess the
relative importance of variation between ears and among
patients in the current study.
IMRT
Each patient’s head and shoulders were immobilized
using a commercially available thermoplastic mask and/
or an individually customized bite block. Computed
tomography (CT) images (2.5-mm slice thickness, 512 ×
512 pixels/slice) were acquired from the top of the ver-
tex to the level of the carina (simulation CT; LightSpeed
RT16, GE Medical Systems, Waukesha, WI, USA). All
patients were treated using IMRT as previously de-
scribed in detail [9]. The mean dose to the cochlea was
Table 1 Characteristics of patients with head and neck cancer
Value—x (%)





Male 381 (90.3 %)
Female 41 (9.7 %)
Tumor site
Larynx 48 (11.4 %)
Hypopharynx 68 (16.1 %)
Oropharynx 54 (12.8 %)
Oral cavity 102 (24.2 %)
Nasopharyngeal carcinoma 150 (35.5 %)
AJCC stage
I 0
II 34 (8.1 %)
III 95 (22.5 %)
IV 293 (69.4 %)
Cochlea mean dose
1–10 43 (10.2 %)
10–20 118 (28 %)
20–30 139 (32.9 %)
30–40 101 (23.9 %)
40–50 15 (3.6 %)
50–60 6 (1.4 %)
Tinnitus (grade 2+)
Yes 49 (11.6 %)
No 373 (88.4 %)
Cochlea mean dose Gy (range) 23.72 (1.73–58.83)
Without grade 2 + Tinnitus 22.44 (1.73–50.26)
With grade 2 + Tinnitus 33.46 (8.72–58.83)
Chemotherapy
Yes 150 (35.5 %)
No 272 (64.5 %)
Abbreviation: AJCC American Joint Committee on Cancer, HNC head and
neck cancer
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kept as low as possible while still achieving the desired
clinical target volume coverage. The dose distributions
were calculated and dose-volume histograms (DVHs)
were generated separately for each cochlea. Two IMRT
techniques were used: simultaneous integrated boost
(SIB), and sequential mode (SQM). Details regarding the
prescribed dose and fractions for the SIB and SQM tech-
niques can be found in previous studies [9, 10]. IMRT was
delivered using the computer-controlled auto-sequencing
segment or the dynamic multileaf collimator of a linear
accelerator (Elekta Precise, Elekta, Crawley, UK) according
to methods reported elsewhere [11]. The prescribed doses
were 66.0–77.4 Gy (median, 70.0 Gy) to the macroscopic
tumor (planning target volume 1 [PTV1]), 54.0–66.0 Gy
(median, 61.2 Gy) to the resected tumor bed (PTV2), and
41.4–54.0 Gy (median, 50.4 Gy) to the subclinical disease
area (PTV3). These were administered at 1.6–2.12 Gy per
fraction using SIB, and 1.8–2.0 Gy per fraction using
SQM with five fractions per week.
According to the Radiation Therapy Oncology Group
0225 and 0615 trials, the planning objectives for PTVs
were a minimum dose > 95 %, and no more than 5 % of
any PTV1 received ≥110 % of the prescribed dose. The
mean dose constraints for the parotid gland were a
mean dose ≤26 Gy or V30Gy ≤50 %. For the oral cavity
excluding the PTV; a mean dose ≤ 40 Gy was used. No
mean dose constraints for the cochlea to avoid tinnitus
have been reported previously. In most cases, the mean
dose constraint to the cochlea was limited to <45 Gy. If
the cochlea was adjacent to or inside the PTV1 or
PTV2, the mean dose to the cochlea could be higher so
as not to sacrifice the PTV coverage. The DVH values
were calculated for each cochlea in all patients. All data
were based on the DVHs obtained using Pinnacle3®
(Philips, Fitchburg, WI, USA) with a bin size resolution
of 0.01 Gy. The resolution of the dose calculation was
2.5 mm for all IMRT plans.
Evaluation of tinnitus
After the completion of radiotherapy, patients were exam-
ined at 4-week intervals until their acute radiation-related
complications subsided. Patients were subsequently
followed-up every 2 months for the first year, and every
3 months thereafter. The evaluations performed at each
follow-up visit included a medical history and physical
examination. Hematology and biochemistry profiles,
chest radiographs, sonography of the abdomen, a bone
scan, and a CT scan of the head and neck were per-
formed at least annually, and were checked whenever
there was any clinical indication. The median follow-up
period before the first detection of grade 2 tinnitus was
23 months (range: 19–37 months). The median follow-
up period for the entire cohort of patients was
51 months (range: 36–77).
According to the Late Effects of Normal Tissues–Sub-
jective, Objective, Management, Analytic (LENT-SOMA)
criteria for tinnitus evaluation, the following five-point
scale was used: 0, none; 1, occasional; 2, intermittent; 3,
persistent; and 4, refractory [12]. Generally, grade 1 toxic-
ities are radiographic findings of negligible clinical conse-
quence that are rarely scored in reports of RT-induced
toxicity. Grade 2 to 4 toxicities generally reflect moderate,
severe, or irreversible functional damage, respectively [13].
The threshold of grade 2+ tinnitus was used as an
endpoint for toxicity. The LENT-SOMA criteria for tin-
nitus did not define the minimum number of observa-
tions used to define the grade of toxicity. In the current
study, a patient with tinnitus ≥ grade 2 on at least two
observations was enrolled. Although this was a retro-
spective study, we assessed the occurrence of tinnitus
after radiotherapy over a long period of time; the median
follow-up period was 23 months. In general, a minimum
follow-up period of 12 months was required before a
patient could be recorded. Since there is a potential for
some patients with otorrhea to develop otitis media
within the first few months following radiotherapy,
which would lead to temporary hearing impairment or
tinnitus, such patients would be observed until the otor-
rhea had subsided. Any tinnitus persisting after the ces-
sation of otorrhea would then be noted. Therefore, the
hearing of all patients was evaluated carefully (including
the presence of tinnitus) before beginning radiotherapy,
and the history of tinnitus was reviewed to rule out
symptoms that were not induced by radiation.
Dose–response modeling
Two commonly used NTCP models, logistic and LKB
[14–21], were used to quantify the relationship between
the incidence of tinnitus toxicity and the dose–response
effects on the cochlea.
A logistic model was used to fit the dose–response for
the incidence of grade 2+ tinnitus as a function of the
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where MD is the mean dose to the cochlea; TD50 is the
mean dose predicting a 50 % risk of complications; and
γ50 is the normalized slope of the dose–response curve;
i.e., the change in NTCP per 1 % change in dose [22].
The family of Lyman-Kutcher-Burman (LKB) models
is the most widely used phenomenological approach
[14–21]. The LKB model is described by three parame-
ters: n, m, and TD50. According to this model, NTCP is
characterized by three equations:



















where Deff is the dose given to the entire volume (Deff is
sometimes referred to as the equivalent uniform dose,
EUD), n is a parameter that considers the volume effect,
and vi is the volume of the dose bin that corresponds to
dose Di in the differential DVH.
The parameter m is a unitless model parameter for
describing the slope of the dose–response curve. In this
study, n was set to 1. Therefore, Deff reduces to an
expression for the mean organ dose (MD). In such spe-








dx ; where t ¼ MD−TD50
m⋅TD50
The best-fit values for TD50, γ50, and m were identified
using maximum-likelihood (ML) analysis, and the 95 %
confidence intervals (CIs) were calculated using the
profile-likelihood method while the parameters were
fixed at the ML estimate [23]. The CIs were calculated
by fixing one parameter at its best-fit value and allowing
the parameter of interest to vary. The 95 % lower and
upper confidence bounds were displaced downward
from the ML peak by a distance determined from the
chi-square distribution, χ2(0.05,1)/2 = 1.92 [24, 25]. In
addition, the guideline TD20 was suggested as the toler-
ance dose that produced a 20 % complication rate within
a specific period of time. All calculations were performed
using the Matlab software (R2010; MathWorks, Natick,
MA, USA). Although the logistic and the Lyman model
yield similar NTCP parameters, they are not precisely
equivalent. However, part of the aims of this study was to
verify the assertion that the Lyman and logistic models are
broadly similar for the same dataset.
Performance evaluation
The model performance was measured using a variety of
validation tools [26–28]. The overall performance was
expressed as a scaled Brier score and checked by an
Omnibus test. The scaled Brier score evaluates the dif-
ferences between actual outcome and predictions, and a
scaled Brier score of 1 would provide optimal agreement
between predictions and actual outcomes. Model per-
formance was also verified using the area under the
receiver operating characteristic curves (AUC), and by
calculating the discrimination slope, which was defined
as the absolute difference between the mean predicted
NTCP-values of patients with and without the evaluated
endpoint [29]. The goodness of fit was further quantified
in terms of calibration; i.e., the agreement between the
predicted and observed outcomes in the dataset, whereas
the Hosmer-Lemeshow test was used to test the agree-
ment between the expected and observed outcomes. A
Hosmer-Lemeshow test value > 0.05 would show agree-
ment between expected and observed outcomes; however,
a value > 0.15 is recommended. The calibration curves
were plotted to show the relationship between predicted
risk and real outcome, and the curved slope of 1 showed a
perfect match. The size of bin used was 10 Gy.
Akaike’s information criterion (AIC) was used to rank
the accepted models. Models with smaller AIC values
were considered to provide a better fit to the data than
were models with larger AIC values [22]. Delta AIC
(ΔAIC) is a measure of each model relative to the best
model. As a rule of thumb, ΔAIC = AICi – minAIC,
whereas a ΔAIC >10 indicates that the model is very
unlikely; values of 3–10 indicate that the model has con-
siderably less support; values <2 suggest substantial evi-
dence for the model and can be considered to be similar
to the best model [30–32].
The negative predictive value (NPV) was also calculated,
which described the rate of avoiding tinnitus when the
guidelines were fulfilled based on dose-volume data. For
example, NPV-TD20 is the fraction of all patients who had
a dose below TD20 and who did not have toxicity. A high
NPV supports the validity of a suggested guideline (TD20),
although plans near the guideline threshold are less risky
than are those distinct from the threshold (TD50). These
analyses were performed for both TD50 and TD20 criteria.
All statistical analyses were performed using the SPSS
19.0 software (SPSS, Chicago, IL, USA).
Results
Three patients who already suffered from problems
related to the vestibulo-cochlear nerve were excluded,
leaving 422 samples from 211 patients to be analyzed.
Forty-nine of the four hundred and twenty-two sam-
ples (11.6 %) developed grade 2+ tinnitus symptoms
determined by a clinician to be caused by IMRT. The
data regarding patient outcome are summarized in
Table 1. The maximum-likelihood estimate of vari-
ance components revealed that there was no signifi-
cant variation among the patient symptoms. This is
consistent with the observations of Honoré et al., and
therefore the two ears of a patient could be used as
independent variables of tinnitus. Average values of
cochlea mean doses for patients with and without tinnitus
were 33.46 Gy and 22.44 Gy, respectively. Univariate ana-
lysis was performed, which revealed a significant relation-
ship between grade 2+ tinnitus and the mean dose to the
cochlea (p < 0.001).
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The fitted dose–response curves (logistic and LKB
NTCP models) for the incidence of grade 2+ tinnitus in
the HNC patient cohort are shown in Fig. 1a, b. The
NTCP-fitted parameters for the logistic and LKB
models were TD50 = 46.31 Gy (95 % CI, 41.46–52.50),
γ50 = 1.27 (95 % CI, 1.02–1.55), and TD50 = 46.52 Gy
(95 % CI, 41.91–53.43), m = 0.35 (95 % CI, 0.30–0.42),
respectively (Table 2). A simple formula can be used for
convenience; i.e., γ50 ≈ 0.4/m. The odds ratio for the logis-
tic model was 1.117 (95 % CI, 1.078–1.157). The suggested
guideline TD20 for the tolerance dose to produce a 20 %
complication rate within a specific period of time was
TD20 = 33.62 Gy (95 % CI, 30.15–38.27) (logistic) and
TD20 = 32.82 Gy (95 % CI, 29.58–37.69) (LKB).
The overall performance and calibration of the NTCP
models for grade 2+ tinnitus toxicity according to the
scaled Brier score, AUC, Hosmer-Lemeshow tests, and
the calibration slope were satisfactory and within the
expected ranges (Table 3). The AUC for the optimal
model was 0.76 (95 % CI, 0.69–0.84) and 0.76 (95 % CI,
0.69–0.84) for the logistic and LKB NTCP models,
respectively. The NPVs are provided in Table 3, and data
revealed that there were very low rates of grade 2+
tinnitus. Smaller AIC values are preferable when compar-
ing two models. However, from the point of view of
ΔAIC, the logistic model is comparable with the LKB
model for fitting this study dataset (ΔAIC = 1.69). Finally,
the calibration slope was ≥0.99 for both models, which
revealed significant agreement between the predicted risk
and observed outcome using both NTCP models (Fig. 2).
The circles in Fig. 2 represent groups of patients with a
specific mean calculated probability. The corrected NTCP
is the trend line between the data points compared with
the reference line, which indicates perfect calibration
between predicted risk and real outcome. Overall, these
data lead to the suggestion that the mean dose to the
cochlea should be maintained at <32 Gy to keep the inci-
dence of grade 2+ tinnitus toxicity at <20 % in IMRT.
Discussion
In this study, the data revealed that the occurrence of
grade 2+ tinnitus after IMRT was 11.6 %. Previous
studies have reported a wide range of incidences of
radiation-induced tinnitus. For example, van der Putten
et al. reported a 12 % incidence with parotid gland
tumors that were treated using local or locoregional uni-
lateral postoperative radiotherapy [4], whereas Tuan et
al. described an incidence of 12 % in nasopharyngeal
cancer using conventional radiotherapy [5]. In addition,
Bakhshandeh reported an occurrence of 13.5 % in head
and neck cancer treated using conventional radiother-
apy [22], whereas Litre reported a much higher inci-
dence of 64 % after the use of fractionated stereotactic
radiotherapy to treat acoustic neuromas [6]. The rea-
sons for these differences could be related to the differ-
ent cancers, treatment techniques, prescription doses
resulting in a difference in dose to the cochlea, or
evaluation grading schemes used.
There are no current standard dose–response con-
straints for the cochlea because no specific NTCP values
have been reported to be associated with an increased
incidence of tinnitus toxicity. Quantitative Analyses of
Normal Tissue Effects in the Clinic (QUANTEC), a tool
resulting from recent concerted efforts among the radio-
therapy community, includes reviews and summaries of
normal tissue toxicity datasets and suggested dose-volume
treatment planning guidelines to reduce the incidence of
side effects [33]. However, there is no QUANTEC guide-
line for the cochlea to avoid tinnitus during IMRT.
QUANTEC recommends a TD25 ≤ 14 Gy for SNHL for
Fig. 1 The fitted dose–response curves of the a logistic and b LKB
NTCP models for the incidence of grade 2+ tinnitus. NTCP normal
tissue complication probability, LKB Lyman-Kutcher-Burman
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hearing at 4 kHz during the stereotactic radiosurgery for
HNCs and vestibular schwannomas, and a TD30 ≤ 45 Gy
for three-dimensional conformal radiotherapy (3D-CRT)
[34]. In the current study, we suggested that the mean
dose to the cochlea should be maintained at <32 Gy
to maintain the incidence of grade 2+ tinnitus toxicity
at <20 % (TD20) during IMRT.
The most serious radiation-induced complication for
the inner ear is SNHL. Published studies show consist-
ently that post-irradiation SNHL occurs in approxi-
mately 30 % of patients treated with definitive radiation
using fields including the inner ear (cochlea) [12].
Although there is no agreement regarding cochlear radi-
ation dose constraints, the minimum cochlear radiation
dose reported as a risk factor for SNHL previously was
45–70 Gy [4, 8, 35, 36]. In the current study, we identi-
fied mean dose constraints of TD50 and TD20 for tin-
nitus; the mean dose to the cochlea must be maintained
below 46 Gy if a 50 % or less probability of complication
is desired. If the probability must be maintained below
20 % then the mean dose to the cochlea should be main-
tained below 32 Gy. These could be particularly advanta-
geous for the treatment of HNC, when large regions
require treatment and the toxicity that affects critical
normal structures can have a profound impact on the
patient function and quality of life [37]. TD50 and TD20
values can provide guidance for setting dose constraints
and predicting the risk of grade 2+ tinnitus during
Table 2 Normal tissue complication probability fitted parameters
NTCP model TD50, Gy (95 % CI) γ50 or m (95 % CI) TD20, Gy (95 % CI)
Logistic 46.31 (41.46–52.50) 1.27 (1.02–1.55) 33.62 (30.15–38.27)
LKB 46.52 (41.91–53.43) 0.35 (0.30–0.42) 32.82 (29.58–37.69)
Abbreviation: CI confidence interval, NTCP normal tissue complication probability, LKB Lyman-Kutcher-Burman, TD50 the dose predicting a 50 % risk of complications,
TD20 the dose predicting a 20 % risk of complications, m a unitless LKB model parameter for describing the slope of the dose–response curve, γ50 a Logistic model
parameter for normalized slope of the dose–response curve
The CIs were calculated by fixing one parameter at its best-fit value and allowing the other parameter to vary
Table 3 System performance evaluation
Logistic NTCP LKB NTCP
AUC 0.76 (0.69–0.84) 0.76 (0.69–0.84)
Brier (scaled) 0.16 0.16
Omnibus P < 0.001 P < 0.001




Abbreviation: NTCP normal tissue complication probability, LKB Lyman-Kutcher-
Burman, NPV Negative predictive value, AUC Area under the receiver operating
characteristic curve, HL Hosmer–Lemeshow test, NPV negative predictive value,
TD50 the dose predicting a 50 % risk of complications, TD20 the dose predicting
a 20 % risk of complications, AIC Akaike’s information criterion
Bin sizes used for Hosmer–Lemeshow test were 15<, 15–25, 25–35, 35–45, >45 Gy
(five bins)
Fig. 2 Calibration curve of the predictive models for grade 2+
tinnitus using a logistic and b LKB NTCP. The plots show the
relationship between estimated risk and real outcome. NTCP
normal tissue complication probability, LKB Lyman-Kutcher-Burman.
Bin size = 6 Gy
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treatment planning. The dose–response model described
in the current study could be useful for comparing the
grade 2+ tinnitus rates among different dose-fractionation
schedules using IMRT for HNC.
In the current study, the dose response of the cochlea
for grade 2+ tinnitus after HNC radiation therapy was
used for NTCP modeling using logistic or LKB models. A
goal of the current study was the retrospective enrollment
of clinical data and its fitting to two different NTCP
models, even though it is known that there is no differ-
ence in the fitting of logistic NTCP or LKB NTCP to the
same dataset. Based on the observation that NTCP
models provide a similar description of the data and the
phenomenological nature of the models, the simplest
model from a computational point of view could be sug-
gested; i.e., the logistic NTCP model. The logistic NTCP
model also has a smaller AIC value. The results presented
in the current study suggest that the clinical data could be
fitted to two NTCP models to obtain similar TD50 values.
In the current study, we defined constraints for the
mean dose to the cochlea instead of the dose-volume
relationship. A dose-volume analysis is unsuitable for
the cochlea because of its small volume and the limita-
tions associated with its delineation [34]. Several studies
have attempted to relate the mean or median cochlear
dose to persistent hearing impairment [8, 34, 38]. All of
these analyses focused on the mean dose given the small
anatomical size of the cochlea. We used the maximal,
mean, and minimal doses to the cochlea as the dose
metrics in the NTCP models, and found that the mean
dose had better correlation than did the other doses.
Therefore, we selected the mean dose for use in the
NTCP modeling and subsequent analyses.
Despite our observations, a large individual study sam-
ple is needed to demonstrate the independent associ-
ation of these NTCP models and the risk of grade 2+
tinnitus toxicity. Moreover, treatment methods might
differ among nations and institutions, and differences in
radiation modalities might yield different types and
levels of tinnitus toxicity. The risk of the cochlea might
also be influenced by the techniques used for treatment
or factors other than the dose, such as baseline patient
risk factors or the co-irradiation of other organs. There-
fore, these parameters should be investigated further.
Conclusion
The dose–response limitation for the cochlea to maintain
the incidence of grade 2+ tinnitus toxicity below 20 % in
IMRT is that the mean dose to the cochlea should be
maintained below 32 Gy. However, NTCP fits can vary
based on a variety of factors, such as patient characteris-
tics, treatment technique, follow up time, etc. Models
should not be extrapolated to other patient populations
without further verification and should be confirmed
before clinical implementation.
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